Human epididymis protein 4 (HE4) in laboratory medicine and an algorithm in renal disorders

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Over the past three decades, cancer antigen (CA) 125 has been utilized for monitoring women who were treated for ovarian cancer. However, this tumor marker showed several limitations such as false elevation in benign pelvic diseases and, in turn, no alterations in ovarian tumors at early stages with a relatively high ratio. For more than ten years, the human epididymis protein 4 (HE4) has become available for the routine laboratory repertoire, showing a higher sensitivity and specificity compared to that of CA125 in ovarian malignancies, but also in other types of tumors based on recently accumulated clinical data. Despite its remarkable diagnostic characteristics, in certain cases, the evaluation of HE4 results may be problematic when patients suffer from additional conditions that may alter HE4 level. Besides the direct effects of age and smoking, menopause status and decreased renal function also show a substantial impact on HE4 values, which should be considered in each patient. For this purpose, we attempted to create a new formula and an algorithm that may be helpful to predict the probability of the presence of ovarian tumor by using the concentrations of HE4 and CA125.

Original languageEnglish
Pages (from-to)35-42
Number of pages8
JournalClinica Chimica Acta
Volume438
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Epididymis
Medicine
Kidney
Tumors
Neoplasms
Proteins
Tumor Biomarkers
Menopause
Ovarian Neoplasms
Smoking
Antigens
Sensitivity and Specificity
Monitoring

Keywords

  • Algorithm
  • EGFR
  • HE4
  • Ovarian cancer
  • Prediction
  • Renal failure

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical
  • Medicine(all)

Cite this

@article{875c756f3f7a4c8a8b1d71cedc940023,
title = "Human epididymis protein 4 (HE4) in laboratory medicine and an algorithm in renal disorders",
abstract = "Over the past three decades, cancer antigen (CA) 125 has been utilized for monitoring women who were treated for ovarian cancer. However, this tumor marker showed several limitations such as false elevation in benign pelvic diseases and, in turn, no alterations in ovarian tumors at early stages with a relatively high ratio. For more than ten years, the human epididymis protein 4 (HE4) has become available for the routine laboratory repertoire, showing a higher sensitivity and specificity compared to that of CA125 in ovarian malignancies, but also in other types of tumors based on recently accumulated clinical data. Despite its remarkable diagnostic characteristics, in certain cases, the evaluation of HE4 results may be problematic when patients suffer from additional conditions that may alter HE4 level. Besides the direct effects of age and smoking, menopause status and decreased renal function also show a substantial impact on HE4 values, which should be considered in each patient. For this purpose, we attempted to create a new formula and an algorithm that may be helpful to predict the probability of the presence of ovarian tumor by using the concentrations of HE4 and CA125.",
keywords = "Algorithm, EGFR, HE4, Ovarian cancer, Prediction, Renal failure",
author = "J. Kappelmayer and P. Antal-Szalm{\'a}s and B. Nagy",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.cca.2014.07.040",
language = "English",
volume = "438",
pages = "35--42",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",

}

TY - JOUR

T1 - Human epididymis protein 4 (HE4) in laboratory medicine and an algorithm in renal disorders

AU - Kappelmayer, J.

AU - Antal-Szalmás, P.

AU - Nagy, B.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Over the past three decades, cancer antigen (CA) 125 has been utilized for monitoring women who were treated for ovarian cancer. However, this tumor marker showed several limitations such as false elevation in benign pelvic diseases and, in turn, no alterations in ovarian tumors at early stages with a relatively high ratio. For more than ten years, the human epididymis protein 4 (HE4) has become available for the routine laboratory repertoire, showing a higher sensitivity and specificity compared to that of CA125 in ovarian malignancies, but also in other types of tumors based on recently accumulated clinical data. Despite its remarkable diagnostic characteristics, in certain cases, the evaluation of HE4 results may be problematic when patients suffer from additional conditions that may alter HE4 level. Besides the direct effects of age and smoking, menopause status and decreased renal function also show a substantial impact on HE4 values, which should be considered in each patient. For this purpose, we attempted to create a new formula and an algorithm that may be helpful to predict the probability of the presence of ovarian tumor by using the concentrations of HE4 and CA125.

AB - Over the past three decades, cancer antigen (CA) 125 has been utilized for monitoring women who were treated for ovarian cancer. However, this tumor marker showed several limitations such as false elevation in benign pelvic diseases and, in turn, no alterations in ovarian tumors at early stages with a relatively high ratio. For more than ten years, the human epididymis protein 4 (HE4) has become available for the routine laboratory repertoire, showing a higher sensitivity and specificity compared to that of CA125 in ovarian malignancies, but also in other types of tumors based on recently accumulated clinical data. Despite its remarkable diagnostic characteristics, in certain cases, the evaluation of HE4 results may be problematic when patients suffer from additional conditions that may alter HE4 level. Besides the direct effects of age and smoking, menopause status and decreased renal function also show a substantial impact on HE4 values, which should be considered in each patient. For this purpose, we attempted to create a new formula and an algorithm that may be helpful to predict the probability of the presence of ovarian tumor by using the concentrations of HE4 and CA125.

KW - Algorithm

KW - EGFR

KW - HE4

KW - Ovarian cancer

KW - Prediction

KW - Renal failure

UR - http://www.scopus.com/inward/record.url?scp=84906329955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906329955&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2014.07.040

DO - 10.1016/j.cca.2014.07.040

M3 - Article

C2 - 25127713

AN - SCOPUS:84906329955

VL - 438

SP - 35

EP - 42

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -